By Fineline Cube 
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) announced the initiation of commercial launch for Cobenfy™ (xanomeline, trospium) in China, marking a significant milestone with the first nationwide prescription issued for the novel oral therapy. The drug was approved in December 2025 for the treatment of schizophrenia in adults.
Cobenfy represents an innovative oral combination therapy featuring xanomeline, an M1/M4-preferring muscarinic acetylcholine receptor agonist, paired with trospium, a muscarinic receptor antagonist. This dual-mechanism approach targets the underlying cholinergic dysfunction in schizophrenia while mitigating peripheral side effects.
Licensing Agreement & Territory Rights
| Partnership Detail | Specification |
|---|---|
| Licensing Partner | Karuna Therapeutics (acquired by Bristol Myers Squibb) |
| Territory | Greater China (Mainland China, Hong Kong, Macau, Taiwan) |
| Rights Granted | Exclusive development, manufacturing, and commercialization |
| Approval Timeline | December 2025 (China NMPA) |
| Commercial Launch | June 2026 |
Product Profile & Mechanism of Action
- Therapeutic Class: First-in-class muscarinic receptor modulator for schizophrenia
- Dual Components:
- Xanomeline: M1/M4-preferring muscarinic agonist targeting central nervous system pathways
- Trospium: Peripherally restricted muscarinic antagonist reducing gastrointestinal and cardiovascular side effects
- Administration: Oral tablet formulation
- Indication: Adult schizophrenia (monotherapy or adjunctive treatment)
- Differentiation: Non-dopaminergic mechanism addressing cognitive and negative symptoms beyond traditional antipsychotics
Market Opportunity & Strategic Significance
- Schizophrenia Burden: Affects approximately 8 million people in China, representing one of the largest patient populations globally
- Treatment Gap: Significant unmet need for therapies addressing cognitive impairment and negative symptoms
- Competitive Landscape:
- Traditional Antipsychotics: Primarily target positive symptoms through dopamine blockade
- Cobenfy Advantage: Novel mechanism potentially improving functional outcomes and quality of life
- Pricing & Reimbursement: Expected premium positioning with potential inclusion in national reimbursement negotiations
Commercial Strategy & Revenue Outlook
- Launch Approach: Targeted rollout to specialized psychiatric centers and academic medical institutions
- Physician Education: Comprehensive training program on novel mechanism and patient selection criteria
- Market Penetration: Initial focus on treatment-resistant patients and those experiencing inadequate response to current therapies
- Revenue Contribution: Analysts project peak annual sales of $300-500 million in Greater China market
- Pipeline Synergy: Strengthens Zai Lab’s neuropsychiatry portfolio alongside existing oncology focus
This commercial launch represents Zai Lab’s successful execution of its strategy to bring innovative therapies to Chinese patients while establishing itself as a leading biopharmaceutical company with both domestic and international partnerships.
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial performance, market adoption, regulatory compliance, and financial projections. Actual results may differ due to competitive pressures, reimbursement challenges, and evolving treatment guidelines.-Fineline Info & Tech